Upcycling excess carbon dioxide with tiny microbes

While some microbes can make people sick or spoil food, others are critical for survival. These tiny organisms can also be engineered to make specific molecules. Researchers reporting in ACS Sustainable Chemistry & Engineering have rewired one such microbe to help tackle greenhouse gases in the atmosphere: It takes in carbon dioxide (CO₂) gas and produces mevalonate, a useful building block for pharmaceuticals.

The increasing concentration of greenhouse gases in the atmosphere has led to widespread global warming. To begin to address the problem, greenhouse gas emissions, including CO₂, need to be significantly reduced. On top of that, the CO₂ already present could be removed. Methods to capture CO­₂ are in development, and one promising option involves microbes. Genetic engineering can modify their natural biosynthetic pathways, turning the microbes into miniature living factories that can produce all sorts of things — for example, insulin.

One potential microbial factory is Cupriavidus necator H16, a bacterium favored thanks to its relatively unfussy nature about what it’s fed. Because it can survive on little more than CO₂ and hydrogen gas, the bacterium is a great candidate for capturing and converting the gases into larger molecules. But even though the microbe’s DNA can be rewired to produce interesting products, it’s not great at remembering those new instructions over time. To put it scientifically, the plasmids (the genetic instructions) are relatively unstable. Katalin Kovacs and colleagues wanted to see if they could improve C. necator’s ability to remember its new instructions and produce useful carbon-based building blocks out of CO₂ gas.

The team got to work hacking C. necator’s biochemical pathways responsible for converting CO₂ into larger six-carbon molecules. The key to improving the plasmid’s stability lies in an enzyme called RubisCo, which allows the bacterium to utilize CO₂. Essentially, the new plasmid was paired to the enzyme, so if a cell failed to remember the new instructions, it would fail to remember how to make RubisCo and die. Meanwhile, the remaining cells with better memories would survive and replicate, passing along the plasmid.

In tests, the newly engineered microbes produced significantly more of the six-carbon molecule mevalonate compared with a control strain. Mevalonate is a molecular building block for all sorts of substances in living and synthetic systems alike, including cholesterol and other steroid molecules with pharmaceutical applications. In fact, this research produced the largest amounts to date of mevalonate from CO₂ or other single-carbon reactants using microbes. The researchers say this is a more economically feasible carbon fixation system than previous systems involving C. necator, and it could be expanded to other microbial strains as well.

The authors acknowledge funding from the Biotechnology and Biological Sciences Research Council and the Engineering and Physical Sciences Research Council of the United Kingdom.

###

The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS’ mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and all its people. The Society is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world’s scientific knowledge. ACS’ main offices are in Washington, D.C., and Columbus, Ohio.

Registered journalists can subscribe to the ACS journalist news portal on EurekAlert! to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.

Note: ACS does not conduct research, but publishes and publicizes peer-reviewed scientific studies.

Follow us: X, formerly Twitter | Facebook | LinkedIn | Instagram